立即与逐渐降低香烟尼古丁含量对烟雾暴露生物标志物的影响:一项随机临床试验
该双盲随机平行对照研究在美国10个中心纳入1250名30天内无戒烟意愿的每日吸烟者,比较立即降至0.4 mg/g尼古丁香烟、5个月内逐渐从15.5 mg/g降至0.4 mg/g、以及维持15.5 mg/g香烟20周对烟雾暴露生物标志物的影响。结果显示,立即降低组较逐渐降低组和对照组的一氧化碳、3-HPMA和PheT曲线下面积均显著更低,而逐渐降低组与对照组之间无显著差异。
要点
- 立即降至0.4 mg/g尼古丁组较逐渐降低组CO平均差异为-4.06 ppm(95%CI -4.89至-3.23),3-HPMA几何均值比为0.83(95%CI 0.77至0.88),PheT几何均值比为0.88(95%CI 0.83至0.93)。
- 立即降低组较对照组CO平均差异为-3.38 ppm(95%CI -4.40至-2.36),3-HPMA几何均值比为0.81(95%CI 0.75至0.88),PheT几何均值比为0.86(95%CI 0.81至0.92)。
- 逐渐降低组与对照组之间CO、3-HPMA和PheT均无显著差异(CO平均差异0.68 ppm,95%CI -0.31至1.67,P=0.18;3-HPMA几何均值比0.98,95%CI 0.91至1.06,P=0.64;PheT几何均值比0.98,95%CI 0.92至1.04,P=0.52)。
- 研究对象为每日吸烟者,平均年龄45岁,549名女性(44%),958名(77%)完成试验。
- 干预为期20周,逐渐降低方案包含5次每月剂量调整。
适用人群与场景
- 美国10个中心招募的每日吸烟者志愿者,30天内无戒烟意愿,基线吸烟2周后进入20周干预。
处置流程与药物剂量
- 立即降低组:香烟尼古丁含量直接降至0.4 mg/g烟草。
- 逐渐降低组:香烟尼古丁含量从15.5 mg/g经5次每月剂量调整降至0.4 mg/g烟草。
- 对照组:维持15.5 mg/g烟草的香烟。
研究设计与关键结果
- 双盲随机平行设计,1250名参与者随机分组,2周基线吸烟加20周干预,主要终点为干预20周期间呼出气CO、尿3-HPMA和尿PheT的浓度-时间曲线下面积组间差异。
- 立即降低组较逐渐降低组CO平均差异-4.06 ppm(95%CI -4.89至-3.23;P<.0055),3-HPMA几何均值比0.83(95%CI 0.77至0.88;P<.0055),PheT几何均值比0.88(95%CI 0.83至0.93;P<.0055)。
- 立即降低组较对照组CO平均差异-3.38 ppm(95%CI -4.40至-2.36;P<.0055),3-HPMA几何均值比0.81(95%CI 0.75至0.88;P<.0055),PheT几何均值比0.86(95%CI 0.81至0.92;P<.0055)。
- 逐渐降低组与对照组之间CO平均差异0.68 ppm(95%CI -0.31至1.67;P=.18),3-HPMA几何均值比0.98(95%CI 0.91至1.06;P=.64),PheT几何均值比0.98(95%CI 0.92至1.04;P=.52),均无显著差异。
证据类型、等级与局限
- 证据类型:双盲随机平行对照试验,10个美国中心,样本量1250例。
- 试验注册号:clinicaltrials.gov NCT02139930。
- 局限:原文未报告局限性。
对床旁实践的改变
- 研究结果提示,在无戒烟意愿的每日吸烟者中,立即将香烟尼古丁降至0.4 mg/g较逐渐降低或维持常规水平可显著降低CO、3-HPMA和PheT反映的烟雾毒性暴露。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The optimal temporal approach for reducing nicotine to minimally or nonaddictive levels in all cigarettes sold in the United States has not been determined.
OBJECTIVES: To determine the effects of immediate vs gradual reduction in nicotine content to very low levels and as compared with usual nicotine level cigarettes on biomarkers of toxicant exposure.
DESIGN, SETTING, AND PARTICIPANTS: A double-blind, randomized, parallel-design study with 2 weeks of baseline smoking and 20 weeks of intervention was conducted at 10 US sites. A volunteer sample of daily smokers with no intention to quit within 30 days was recruited between July 2014 and September 2016, with the last follow-up completed in March 2017.
INTERVENTIONS: (1) Immediate reduction to 0.4 mg of nicotine per gram of tobacco cigarettes; (2) gradual reduction from 15.5 mg to 0.4 mg of nicotine per gram of tobacco cigarettes with 5 monthly dose changes; or (3) maintenance on 15.5 mg of nicotine per gram of tobacco cigarettes.
MAIN OUTCOMES AND MEASURES: Between-group differences in 3 co-primary biomarkers of smoke toxicant exposure: breath carbon monoxide (CO), urine 3-hydroxypropylmercapturic acid (3-HPMA, metabolite of acrolein), and urine phenanthrene tetraol (PheT, indicator of polycyclic aromatic hydrocarbons) calculated as area under the concentration-time curve over the 20 weeks of intervention.
RESULTS: Among 1250 randomized participants (mean age, 45 years; 549 women [44%]; 958 [77%] completed the trial), significantly lower levels of exposure were observed in the immediate vs gradual reduction group for CO (mean difference, -4.06 parts per million [ppm] [95% CI, -4.89 to -3.23]; P < .0055), 3-HPMA (ratio of geometric means, 0.83 [95% CI, 0.77 to 0.88]; P < .0055), and PheT (ratio of geometric means, 0.88 [95% CI, 0.83 to 0.93]; P < .0055). Significantly lower levels of exposure were observed in the immediate reduction vs control group for CO (mean difference, -3.38 [95% CI, -4.40 to -2.36]; P < .0055), 3-HPMA (ratio of geometric means, 0.81 [95% CI, 0.75 to 0.88]; P < .0055), and PheT (ratio of geometric means, 0.86 [95% CI, 0.81 to 0.92]; P < .0055). No significant differences were observed between the gradual reduction vs control groups for CO (mean difference, 0.68 [95% CI, -0.31 to 1.67]; P = .18), 3-HPMA (ratio of geometric means, 0.98 [95% CI, 0.91 to 1.06]; P = .64), and PheT (ratio of geometric means, 0.98 [95% CI, 0.92 to 1.04]; P = .52).
CONCLUSIONS AND RELEVANCE: Among smokers, immediate reduction of nicotine in cigarettes led to significantly greater decreases in biomarkers of smoke exposure across time compared with gradual reduction or a control group, with no significant differences between gradual reduction and control.
TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02139930.
参考来源
- Hatsukami DK, Luo X, Jensen JA, et al. Effect of Immediate vs Gradual Reduction in Nicotine Content of Cigarettes on Biomarkers of Smoke Exposure: A Randomized Clinical Trial. JAMA. 2018. PMID: 30193275. doi:10.1001/jama.2018.11473
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。